Skip to main content
ABEO
NASDAQ Life Sciences

FDA Approves FAYUVI Gene Therapy, Triggering Milestone Payments for Abeona

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$5.744
Mkt Cap
$319.659M
52W Low
$4
52W High
$7.65
52W Position info
44% above low
Off High info
25% below high
Rel. Volume info
2.3× avg
Market data snapshot near publication time

ABEO sits 44% above its 52-week low of $4 on elevated volume (2.3× avg).

Summary

The FDA approved Ultragenyx's FAYUVI gene therapy for Sanfilippo syndrome type A, a program Abeona originally developed as ABO-102 and out-licensed in 2022. Under that agreement, Abeona is now eligible for commercial milestone payments and royalties on future sales. This is a meaningful value-creation event for Abeona, validating its foundational R&D and adding a potential revenue stream beyond ZEVASKYN. The approval also de-risks the partnered asset and may improve Abeona's standing in future licensing discussions. Watch for disclosure of milestone amounts or royalty rates in upcoming filings.

At the time of this announcement, ABEO was trading at $5.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $319.7M. The 52-week trading range was $4.00 to $7.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ABEO - Latest Insights

ABEO
Nov 09, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.52
Real-time Price: $2.36 info
Change: -$0.160 (-6%) info
Market Cap: $131.438M info
ABEO
Nov 09, 2026, 11:06 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $2.62
Real-time Price: $2.36 info
Change: -$0.255 (-10%) info
Market Cap: $131.438M info
ABEO
Nov 09, 2026, 6:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $2.36 info
Change: -$1.65 (-41%) info
Market Cap: $131.438M info
ABEO
Nov 09, 2026, 6:35 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $2.36 info
Change: -$1.65 (-41%) info
Market Cap: $131.438M info
ABEO
Nov 09, 2026, 6:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.18
Real-time Price: $2.36 info
Change: -$1.82 (-44%) info
Market Cap: $131.438M info